Shanghai Pharma Plans To Acquire New Asiatic, Shanghai Asia Pioneer
This article was originally published in PharmAsia News
Shanghai Pharmaceutical recently announced its plan to acquire 96.9 and 100 percent stakes in New Asiatic Pharmaceutical and Shanghai Asia Pioneer Pharmaceutical for RMB 1.488 billion, which will enable Shanghai Pharmaceutical to list its entire antibiotics business
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.